The authors investigated the safety and activity of ibrutinib in previously untreated and relapsed or refractory CLL with TP53 aberrations. The activity and safety profile of single-agent ibrutinib in CLL with TP53 aberrations is encouraging and supports its consideration as a novel treatment option for patients with this high-risk disease in both first-line and second-line settings.

READ FULL ARTICLE Curated publisher From Mdlinx